GILDKite, A Gilead CompanyRunning, no new patients
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
Multiple Myeloma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 452 (final count)
- Started
- Aug 23, 2024
- Main results expected
- Jul 2028
- Fully finished
- Jul 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS)
Measured over: Up to 4 years
Minimal Residual Disease (MRD) Complete Response (CR) Rate at 9 Months
Measured over: Up to 9 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06413498 · record last updated 2026-07-29 · checked 2026-11-09 15:47 UTC